Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity (2016 - 2025)

Ocular Therapeutix has reported Common Equity over the past 13 years, most recently at $654.3 million for Q4 2025.

  • Quarterly results put Common Equity at $654.3 million for Q4 2025, up 107.49% from a year ago — trailing twelve months through Dec 2025 was $654.3 million (up 107.49% YoY), and the annual figure for FY2025 was $654.3 million, up 107.49%.
  • Common Equity for Q4 2025 was $654.3 million at Ocular Therapeutix, up from $258.2 million in the prior quarter.
  • Over the last five years, Common Equity for OCUL hit a ceiling of $654.3 million in Q4 2025 and a floor of $3.1 million in Q2 2023.
  • Median Common Equity over the past 5 years was $87.7 million (2021), compared with a mean of $180.8 million.
  • Biggest five-year swings in Common Equity: crashed 95.31% in 2023 and later skyrocketed 12135.02% in 2024.
  • Ocular Therapeutix's Common Equity stood at $88.0 million in 2021, then plummeted by 59.8% to $35.4 million in 2022, then soared by 157.59% to $91.1 million in 2023, then skyrocketed by 246.03% to $315.3 million in 2024, then soared by 107.49% to $654.3 million in 2025.
  • The last three reported values for Common Equity were $654.3 million (Q4 2025), $258.2 million (Q3 2025), and $305.9 million (Q2 2025) per Business Quant data.